These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 20671370)
1. Heparin cofactor II attenuates vascular remodeling in humans and mice. Aihara K Circ J; 2010 Aug; 74(8):1518-23. PubMed ID: 20671370 [TBL] [Abstract][Full Text] [Related]
2. Heparin cofactor II as a novel vascular protective factor against atherosclerosis. Aihara K; Azuma H; Akaike M; Sata M; Matsumoto T J Atheroscler Thromb; 2009 Oct; 16(5):523-31. PubMed ID: 19729870 [TBL] [Abstract][Full Text] [Related]
3. Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice. Aihara K; Azuma H; Akaike M; Ikeda Y; Sata M; Takamori N; Yagi S; Iwase T; Sumitomo Y; Kawano H; Yamada T; Fukuda T; Matsumoto T; Sekine K; Sato T; Nakamichi Y; Yamamoto Y; Yoshimura K; Watanabe T; Nakamura T; Oomizu A; Tsukada M; Hayashi H; Sudo T; Kato S; Matsumoto T J Clin Invest; 2007 Jun; 117(6):1514-26. PubMed ID: 17549254 [TBL] [Abstract][Full Text] [Related]
13. Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice. Vicente CP; He L; Tollefsen DM Blood; 2007 Dec; 110(13):4261-7. PubMed ID: 17878401 [TBL] [Abstract][Full Text] [Related]
14. Decreased heparin cofactor II activity is associated with impaired endothelial function determined by brachial ultrasonography and predicts cardiovascular events. Huang PH; Leu HB; Chen JW; Wu TC; Lu TM; Yu-An Ding P; Lin SJ Int J Cardiol; 2007 Jan; 114(2):152-8. PubMed ID: 16650906 [TBL] [Abstract][Full Text] [Related]
15. Plasma heparin cofactor II activity is inversely associated with left atrial volume and diastolic dysfunction in humans with cardiovascular risk factors. Ise T; Aihara K; Sumitomo-Ueda Y; Yoshida S; Ikeda Y; Yagi S; Iwase T; Yamada H; Akaike M; Sata M; Matsumoto T Hypertens Res; 2011 Feb; 34(2):225-31. PubMed ID: 21107326 [TBL] [Abstract][Full Text] [Related]
16. [Heparin cofactor II, a thrombin inhibitor with a still not clarified physiologic role]. Rossi EB; Duboscq CL; Kordich LC Medicina (B Aires); 1999; 59(1):95-104. PubMed ID: 10349131 [TBL] [Abstract][Full Text] [Related]
17. High plasma heparin cofactor II activity protects from restenosis after femoropopliteal stenting. Schillinger M; Exner M; Sabeti S; Mlekusch W; Amighi J; Handler S; Quehenberger P; Kalifeh N; Wagner O; Minar E Thromb Haemost; 2004 Nov; 92(5):1108-13. PubMed ID: 15543340 [TBL] [Abstract][Full Text] [Related]
18. Heparin cofactor II significance for the inhibition of thrombin at the injured vessel wall. Pasche B; Swedenborg J; Frebelius S; Olsson P Thromb Res; 1991 Jun; 62(5):409-19. PubMed ID: 1896960 [TBL] [Abstract][Full Text] [Related]
19. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. Huang SS; Huang PH; Chen YH; Sung SH; Chiang KH; Chen JW; Lin SJ Coron Artery Dis; 2008 Dec; 19(8):597-602. PubMed ID: 18971786 [TBL] [Abstract][Full Text] [Related]
20. Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II. He L; Giri TK; Vicente CP; Tollefsen DM Blood; 2008 Apr; 111(8):4118-25. PubMed ID: 18281504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]